

Published in final edited form as:

Nat Genet. 2015 December ; 47(12): 1449–1456. doi:10.1038/ng.3424.

Multi-ethnic genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis

A full list of authors and affiliations appears at the end of the article.

These authors contributed equally to this work.

Abstract

Genetic association studies have identified 21 loci associated with atopic dermatitis risk predominantly in populations of European ancestry. To identify further susceptibility loci for this common complex skin disease, we performed a meta-analysis of >15 million genetic variants in 21,399 cases and 95,464 controls from populations of European, African, Japanese and Latino ancestry, followed by replication in 32,059 cases and 228,628 controls from 18 studies. We identified 10 novel risk loci, bringing the total number of known atopic dermatitis risk loci to 31 (with novel secondary signals at 4 of these). Notably, the new loci include candidate genes with roles in regulation of innate host defenses and T-cell function, underscoring the important contribution of (auto-)immune mechanisms to atopic dermatitis pathogenesis.

Atopic dermatitis (eczema) is a common inflammatory skin disease affecting 15–30% of children and 5–10% of adults¹. Its pathogenesis involves skin barrier abnormalities and a T-cell-driven cutaneous inflammation. Atopic dermatitis has significant genetic contributions, with heritability estimates of up to 90%² in Europeans. The strongest known risk factors are null mutations of the filaggrin (*FLG*) gene, resulting in epidermal barrier deficiency^{3–5}. Genome-wide association (GWA) studies have identified 20 additional loci (10 in Europeans, 8 in Japanese, 2 in Chinese populations), mostly implicated in immune dysregulation^{6–12}. Genetic modeling suggests further loci may be identified with well-powered GWAS¹³. We therefore carried out a multi-ethnic meta-analysis of 26 studies comprising 21,399 cases and 95,464 controls imputed to the 1000 Genomes Project Phase 1

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

Corresponding author: Lavinia Paternoster l.paternoster@bristol.ac.uk.

Methods-only URLs

Gene Expression Omnibus www.ncbi.nlm.nih.gov/geo/profiles

MGI database www.informatics.jax.org

Competing interests statement

C.T, D.A.H, and J.Y.T. are employees of and own stock or stock options in 23andMe, Inc.

K.M.G. has received reimbursement for speaking at conferences sponsored by companies selling nutritional and pharmaceutical products. He is part of an academic consortium that has received funding from Abbott Nutrition, Nestec and Danone.

The University of Groningen has received money for D.S.P regarding an unrestricted educational grant for research from Astra Zeneca. Fees for consultancies were given to the University of Groningen by Astra Zeneca, Boehringer Ingelheim, Chiesi, GSK, Takeda and TEVA.

A.C. reports personal fees from AstraZeneca, personal fees from Novartis, personal fees from ThermoFisher outside the submitted work. A.S reports personal fees from GSK, personal fees from ThermoFisher outside the submitted work.

reference panel (Supplementary Note 1 & Supplementary Table 1). 15,539,996 variants with 1% MAF were analyzed.

A fixed effects meta-analysis of the 22 European studies identified 21 genome-wide significant ($p < 5 \times 10^{-8}$) loci (Table 1, Fig 1, Supplementary Figs 1-4), and a multi-ethnic meta-analysis identified an additional 6 loci with \log_{10} Bayes Factor > 6.1 , 4 of which (10q21.2, 6p21.33, 11p13, 2p13.3) also showed nominal association in the European analysis (Table 1). These 27 loci included all 11 loci previously associated with atopic dermatitis in Europeans and 5 loci originally reported in Japanese. Three Japanese loci (6p21.33, 10q21.2, 2q12.1) were also strongly associated in the European analysis, whereas two (3q13.2, 11p15.4) may represent Japanese-specific signals (Supplementary Figs 1&2), with the European confidence interval ruling out all but very small effects ($OR < 1.03$, Table 1). Furthermore, a locus originally reported in a Chinese GWAS (20q13.33) showed association in Europeans. We identified 11 novel loci for atopic dermatitis. Four (11q24.3, 10p15.1, 8q21.13, 2p25.1) were previously associated with self-reported allergy¹⁴, and another (8q21.13) with asthma¹⁵. Two novel variants (5p13.2 and 2p25.1) showed statistically significant evidence of heterogeneity between European and non-European studies (Cochran's Q $p \sim 0.01$, Supplementary Table 2). Both showed little evidence for association in non-Europeans (particularly Japanese, Supplementary Fig.2). The CIs also overlapped for all variants when comparing pediatric (defined as onset by age 6) with any-age onset studies (Supplementary Fig.3). Within Europeans there was some evidence of heterogeneity in effect sizes between studies amongst known variants (e.g. 11q13.5 $I^2 = 62.9\%$, $p < 0.0001$; 11p13 $I^2 = 55.6\%$, $p = 0.0011$) but little evidence amongst novel variants (I^2 range = 0-40%, all $p > 0.02$, Supplementary Fig.2). Nevertheless, studies with phenotype definition based on a dermatological exam tended to report larger effect sizes than studies using self-report (Supplementary Fig.4), which is to be expected, assuming a moderate degree of phenotypic misclassification in the latter. The inclusion of studies utilizing self-report is therefore likely to bias estimates of the effect size towards the null, and this should be borne in mind when interpreting the odds ratios from our study. Given the primary aim of GWA studies is the detection of novel loci, the increase in sample size achieved by including these studies is so large that any potential detrimental effect on statistical power is more than outweighed and the expected direction of bias means there is unlikely to be an issue of spurious findings (corroborated by Supplementary Fig.4)."

Seven of the 21 established asthma loci¹⁵⁻²⁰, 7 of the 10 allergic sensitization loci²¹, and 6 of 14 self-reported allergy loci¹⁴ showed association with atopic dermatitis ($p < 0.05$), all with consistent directions of effect, supporting common atopic mechanisms in atopic dermatitis and allergy (Supplementary Table 3). However, several studies used here contribute to multiple GWASs, which may bias this overlap. Nevertheless, a substantial proportion of the loci associated with other atopic conditions appear not to be strongly associated with atopic dermatitis.

Twenty-one of the 27 atopic dermatitis-associated loci have previously been implicated in other immune-mediated traits (Supplementary Table 4), most notably inflammatory bowel disease (IBD) and psoriasis. We therefore compared significant results from GWAS of IBD²², psoriasis²³, ankylosing spondylitis²⁴, multiple sclerosis²⁵, rheumatoid arthritis²⁶ and

type 1 diabetes²⁷ with results from our present study of atopic dermatitis. Of 163 established IBD risk variants, 39 reached $p < 0.05$ for atopic dermatitis (Supplementary Table 5, 8.1 expected, $p = 2.4 \times 10^{-16}$), 35 with the same direction of effect (sign test $p < 0.0001$), consistent with the observational association between the two diseases²⁸⁻³⁰. Of the 36 known psoriasis variants, 15 reached $p < 0.05$ for atopic dermatitis (Supplementary Table 6, 1.8 expected, $p = 6 \times 10^{-11}$), 10 with the same direction of effect (sign test $p = 0.30$). However, these conditions rarely clinically co-occur³¹ and the most strongly associated genetic variants show opposite directions of effect³². Therefore our results, suggesting a more complex genetic relationship, might warrant further investigation. SNPs robustly associated with other auto-immune diseases were also more likely to be nominally associated with atopic dermatitis than expected by chance, but there was little evidence of any consistency in direction of effect (Supplementary Tables 7–10). These findings did not appear to be affected by contamination by common controls across studies. Analyses performed excluding common cohorts, yielded similar results (data not shown).

Conditional analysis showed evidence for secondary independent signals at 4 known atopic dermatitis loci (2q12.1, 4q27, 11p13, 5q31.1, Supplementary Table 11), one of which (5q31.1) has been previously reported⁹. In the epidermal differentiation complex (1q21.2–3, where *FLG* is located) the signals near *MRPS21* (rs7512552) and *IL6R* (rs12730935 or the known functional mutation rs2228145) were independent from *FLG*, whereas the top signal near *LCE3E* (rs61813875) appears to be partially tagging the R501X *FLG* mutation ($r^2 = 0.49$) and showed no significant residual association ($P > 0.05$) after conditioning on the 4 most prevalent *FLG* mutations (Supplementary Tables 12&13).

To identify additional variants of biological relevance not reaching genome-wide significance, we applied gene-set enrichment analysis using Meta-Analysis Gene-set Enrichment of variaNT Associations (MAGENTA)³³ (Supplementary Table 14). A significant enrichment of 22 partially overlapping gene-sets ($FDR \leq 0.01$) related to innate immune signaling and T-cell polarization was observed (Supplementary Fig.5).

For replication, we selected the lead SNPs from the 11 novel loci, 9 candidate SNPs from the MAGENTA analysis (with $p < 10^{-5}$ mapping to gene-sets with $FDR < 0.05$), and 3 SNPs representing potentially novel secondary signals. These were investigated in 18 studies (32,059 cases and 228,628 controls, Supplementary Table 1). Amongst the European studies, 11 of the 20 novel loci reached a Bonferroni-corrected threshold ($\alpha = 0.0025$) with 1-sided tests in a fixed effects analysis (Table 2). However, one of these showed evidence of heterogeneity (10p15.1, $p = 0.041$) and was not significant in a random effects analysis ($p = 0.019$, Supplementary Table 15). Two of the gene-set selected SNPs reached genome-wide significance in the combined analysis (2q37.1, 12q15). A random effects analysis of all replication cohorts (European and other ethnicities) show broadly consistent results (though only 6 reach genome-wide significance), with no clear population-specific effects (Supplementary Table 16 & Fig.6).

All 3 secondary signals showed significant association in the replication-phase conditional analysis (Supplementary Table 11).

As a preliminary step towards understanding the functional underpinnings of the atopic dermatitis genetic associations, we established a ‘credible set’ of SNPs (all with strong association) for each locus as described in the online methods³⁴. We reviewed these SNPs’ functional annotations in ENCODE Consortium and Roadmap Epigenomics Consortium data, evaluated expression quantitative trait locus (eQTL) effects in MuTHER³⁵, reviewed evidence of differential expression, and surveyed relevant mouse mutants (see Supplementary Note 2 and Tables 17–21). Regions of DNase hypersensitivity from the ENCODE and Roadmap data^{36,37} were strongly enriched for atopic dermatitis association compared to the rest of the genome (Supplementary Fig.7 & Table 22), particularly in immune cells (Th0, Th1, Th17 $p < 0.0001$), this enrichment was observed well below the genome-wide significance threshold, indicating the presence of additional undetected risk variants. We observed multiple cis-eQTLs (Bonferroni-corrected $p < 7 \times 10^{-4}$) in lymphoblastoid cell lines (LCLs) or skin (Supplementary Tables 17&19). The most significant were two variants from the credible set at 2p13.3, which were strong eQTLs for CD207/langerin in skin (rs4852714 $p = 1.23 \times 10^{-10}$, rs6723629 $p = 1.67 \times 10^{-10}$, LD with lead SNP $r^2 = 0.56$, $D' = 0.96$, and $r^2 = 0.53$, $D' = 0.93$, respectively, 99% posterior probability that atopic dermatitis and eQTL signals colocalize). rs4852714 is also in an open-chromatin region with histone marks indicative of promoter/enhancer activity in LCLs (Supplementary Tables 18,19 & Fig.8). *CD207* encodes an intracellular pattern recognition receptor expressed in subpopulations of dendritic cells, in particular epidermal Langerhans cells (LCs) which play a vital role in the induction of tolerance and direction of adaptive immune responses³⁸. CD207 binds to carbohydrates present e.g. on microorganisms and exerts anti-viral/anti-fungal defense mechanisms³⁹. Of note, atopic dermatitis is characterized by an increased susceptibility towards skin infection with pathogens such as *Staphylococcus aureus*, herpes simplex virus, and *Malassezia* species⁴⁰, and differences in langerin function might contribute to this dysregulated cutaneous immunity.

There is longstanding evidence that skin barrier defects and inappropriate immune responses to environmental antigens¹ contributes to atopic dermatitis. However, evidence for autoimmune mechanisms, in particular in the context of progression to the chronic phase, has only recently emerged⁴¹. Interestingly, the majority of our novel susceptibility loci harbor candidate genes with functional annotations related to autoimmunity. At 14q13.2, the lead SNP (rs2038255) is intronic to *PPP2R3C* (a protein phosphatase component regulating B-cell maturation and survival), the dysregulation of which has been associated with murine autoimmunity⁴² and the signal colocalizes with a strong *KIAA0391* eQTL signal (Supplementary Table 19). The lead 5p13.2 variant (rs10214237) is located 4kb downstream of the gene encoding the alpha-chain of the IL7 receptor (IL7R), which is a key mediator in T-cell-driven autoimmunity and inflammation⁴³. Of interest, the credible set contains an *IL7R* missense variant (rs6897932, $p = 1.6 \times 10^{-7}$, $r^2 = 0.94$ with lead SNP), which displays the same effect direction with multiple sclerosis^{44,45}. The risk allele leads to an enhanced bioavailability of IL7⁴⁶, which in mice causes severe dermatitis with intense pruritus and high IgE levels, i.e. atopic dermatitis-like features⁴⁷. Likewise, as part of the autosomal-dominant hyper-IgE syndrome, rare dominant negative mutations in the gene encoding *STAT3* (in which our lead 17q21.2 variant is intronic) cause severe dermatitis and high serum IgE levels, as well as recurrent *S.aureus* skin infections, which may be driven by

impaired Th17 cell differentiation and effector function^{48,49}. *STAT3* might thus represent an example for risk gene/pathway shared between a complex trait and a related Mendelian condition^{50,51}, harboring highly penetrant severe effect rare mutations and common milder effect variants. At 8q21.13, the closest candidate gene is *ZBTB10* encoding a zinc finger protein, which is a putative repressor of the Sp1, Sp3 and Sp4 transcription factors⁵². Variants in moderate LD ($r^2 > 0.7$) with the lead variant for atopic dermatitis were previously associated with self-reported allergy¹⁴ and a combined asthma and hay fever phenotype⁵³. However, although not excluding *ZBTB10* as the causal gene, the credible SNP set comprises a 47kb interval on the other side of a recombination peak (60cM/Mb). The variant most likely to be regulatory amongst this set, deletion rs5892724 ($r^2 = 0.82$ with lead SNP), is located in open chromatin in several cell types including CD4+ helper T-cells, and affects a *STAT3* binding site^{49,54}. At 11q24.3 the most plausible candidate gene is *ETS1*, which encodes a transcription factor with a range of immune functions including Th17 and B-cell differentiation and function; *ETS1*-deficient mice display autoimmune features⁵⁵. *ETS1* appears to be additionally involved in keratinocyte differentiation and formation of the cornified envelope⁵⁶. Additional variants identified through the gene-set approach implicate genes with cytokine signaling functions (*INPP5D*, *TRAF3*, *SOCS3* and a cytokine cluster on 12q15).

In conclusion, we have identified 10 new loci robustly associated with atopic dermatitis in Europeans (6 of which also reach genome-wide significance in random effects analysis across studies of all ethnicities), bringing the total number of susceptibility loci to 31 (24 in Europeans), with evidence of secondary signals at 4 of these. Altogether, in the subset of European studies with clinically defined cases, previously established and newly identified variants explain approximately 12.3% and 2.6% of the variance in liability, respectively (Supplementary Table 23). All novel susceptibility loci are related to (auto-)immune regulation, in particular innate signaling and T-cell activation and specification, and there appears to be a substantial genetic overlap with other inflammatory and autoimmune diseases. Whilst not detracting from the importance of maintaining the skin barrier in the prevention and treatment of atopic dermatitis, our findings lend support to new therapeutic approaches targeted at immune modulation⁵⁷.

ONLINE METHODS

GWAS meta-analysis

We carried out genome-wide association (GWA) analysis for atopic dermatitis case/control status in 26 individual studies (Supplementary Table 1), comprising a total of 21,399 cases and 95,464 controls. The majority of these studies included individuals of only European ancestry (22 studies, 18,900 cases, 84,166 controls). We also included one study of Japanese individuals (RIKEN, 1,472 cases, 7,966 controls), one study of African American individuals (SAPPHIRE, 422 cases and 844 controls), one study of Latin American individuals (GALA II, 300 cases, 1,592 controls) and one study with individuals of mixed non-European ancestry (Generation R, 305 cases, 896 controls).

Each cohort separately imputed their genetic data to 1000 Genomes Project Phase 1 (the majority to the March 2012 release, Supplementary Table 1) and carried out GWA analysis

across all imputed variants. Before meta-analysis we restricted each study to only those variants with minor allele frequency (MAF)>1% and moderate imputation quality score ($R_{sq}>0.3$ for variants imputed in MACH and $proper\ info>0.4$ for IMPUTE). For some cohorts additional quality control filters were applied (full methods for each study are available in Supplementary Note 1).

Meta-analysis was conducted for Europeans only in GWAMA (using fixed effects) and for all ethnicities combined in MANTRA⁶⁰. Rather than imposing a fixed or random effects model, MANTRA accounts for the heterogeneity of effects between ethnicities by allowing the studies to cluster according to allele frequency profile (and hence population genetic similarity). To prevent very small European studies (with less precise estimates of the allele frequencies) from having undue weight in our analysis we fixed the Europeans to cluster together by using the European fixed effects results in the MANTRA analysis. Variants with $p<5\times 10^{-8}$ in the European analysis were considered to be associated, as were any additional variants with (\log_{10}) Bayes Factor (BF)>6.1 (equivalent to $p<5\times 10^{-8}$)⁶¹ in the MANTRA analysis. Each locus is represented in the results table by the variant with the strongest evidence for association. Heterogeneity was assessed using the I^2 statistic and Cochran's Q test. Meta-analysis results were also stratified according to ethnicity, method of case diagnosis and age of onset to explore sources of heterogeneity.

For the Epidermal-differentiation complex region (where the *FLG* gene is located and which has previously shown complex association results), we repeated the association tests (across the region between 150.2–154.5Mb on chromosome 1) conditioning on the four most common *FLG* variants (R501X, 2282del4, R2447X, S3247X) in the individual studies where these were available (10 studies, 20,384 individuals, Supplementary Table 12). These were meta-analyzed to identify whether there were any remaining independent association signals in this region.

Identification of independent secondary signals at associated loci

To identify secondary independent signals at each of the other associated loci, we carried out conditional analysis of the European meta-analysis results using GCTA⁶², with the ALSPAC 1000 Genomes imputation (restricted to variants with MAF>1% and imputation quality $proper\ info\ score>0.8$) serving as the reference. The regions tested were ± 250 kb surrounding the top hit at each locus. Locus specific significance thresholds were estimated by first calculating the effective number of tests in each 500kb region using Nyholt's procedure⁶³ and the 1000 Genomes reference data (European). For each locus we estimated the new threshold for locus-wide error rate of 5% by dividing alpha (0.05) by the corresponding number of effective tests in that region (α -values are shown in Supplementary Table 11). For 4q27 we defined the region as ± 500 kb as a known hit was just less than 500kb from the top SNP in our analysis. We conditioned each region on the top hit from our meta-analysis. Any variant that surpassed the locus-specific threshold was considered an independent secondary signal.

MAGENTA gene-set enrichment analysis

We tested our meta-analysis results for enriched gene-sets using MAGENTA³³. This method assigns SNPs to genes based on genomic distance (SNPs are assigned if within 110kb upstream or 40kb downstream of each gene), and generates gene-based summary p-values. Subsequently, genes are assigned to gene-sets (using curated repositories including GO-data, Biocarta, PANTHER, KEGG, etc.) and each gene-set is assigned a p-value by comparing gene summary p-values to a null model where SNPs are drawn randomly 10,000 times (normalizing for the number of SNPs genotyped in each gene) and controlling for false discovery rate (FDR) at $\alpha=0.05$. ~10,000 gene-sets were tested. As MAGENTA requires a p-value as input and to take account of the differing effects between populations, we re-analyzed our meta-analysis of all studies using a random effects model, to serve as input to the MAGENTA analysis. All genes in the HLA region (chr6:29710331–33150000) were removed from the analysis. In order to identify additional variants of interest to take forward to replication we examined any pathway with $FDR < 0.05$. From these gene-sets we took forward to replication any additional loci with a genetic variant $p < 10^{-5}$.

Cross-phenotype comparisons

The NHGRI GWAS catalog⁶⁴ was mined for traits with reported associations at each of our genome-wide significant loci. To further investigate the genetic overlap between atopic dermatitis and auto-immune diseases, we took the genome-wide significant loci from recent GWAS of IBD²² and psoriasis²³ ankylosing spondylitis²⁴, multiple sclerosis²⁵, rheumatoid arthritis²⁶ and type 1 diabetes²⁷ and extracted the atopic dermatitis results for these variants from our European discovery GWAS, noting whether the variant was associated ($p < 0.05$) with atopic dermatitis (testing enrichment of overlap using the 2-sided binomial exact test) and carried the same or opposite direction of effect between the two traits (tested using the sign test).

Replication

The top SNP from the 11 novel associated regions ($\log_{10}BF > 6.1$ or $p < 5 \times 10^{-8}$) were taken forward to replication, along with 9 suggestively associated SNPs ($p < 10^{-5}$) that were in genes highlighted in the MAGENTA analysis as good candidates. In addition, we included any variants with evidence for being secondary independent signals at associated loci. Replication consisted of 18 studies (32,059 cases and 228,628 controls) with genome-wide imputed data available or custom genotyping (Supplementary Table 1). Studies of European ethnicity were combined in fixed effects meta-analyses in GWAMA. We also carried out random effects meta-analysis for the European studies to assess association for variants which showed evidence of heterogeneity ($p < 0.05$). Significant association in the replication phase was determined by 1-sided p-values meeting a Bonferroni-corrected threshold ($\alpha = 0.05/20 = 0.0025$). Random effects meta-analyses of replication studies of all ethnicities were also carried out and forest plots examined for evidence of population-specific effects. For the replication of the three secondary signals, the secondary SNPs were tested for association after conditioning on the top SNP in each of the European cohorts. These results were then combined in fixed effects meta-analyses.

Credible sets

In order to assemble a sensible list of variants at each locus for functional look-ups, we constructed credible sets³⁴ that represent those SNPs most likely to be causal based on statistical evidence from the MANTRA analysis (or from the European analysis for the three variants that appeared to be European-specific). The European-only GWAS was repeated in MANTRA to generate BFs required for the credible set analysis. Bayes factors were used to calculate posterior probabilities for all SNPs in each region ($\pm 1\text{Mb}$), the minimum set of SNPs that had a cumulative posterior probability of at least 95% made up each credible set. These sets can be interpreted similar to confidence intervals, in that assuming the association signal at a locus can be attributed to a single causal variant (and that the true causal variant is included in the analysis and has been well-imputed), the 95% credible set contains that causal variant with 95% probability. Given that a 1000 Genomes imputation analysis may not include the true causal variant or that the associations may be driven by more than one causal variant, we do not expect these credible sets to necessarily contain the causal variants at the suggested 95% probability. Nevertheless, they demonstrate in addition to the ‘top SNP’, which neighbouring variants also show strong association with atopic dermatitis and we find them useful in assessing the size of the regions of interest and for defining a set of variants to follow-up. As the posterior probabilities for the MAGENTA identified credible sets are extremely large (due to the weaker signals at these loci), we instead carried out functional look-ups for all variants with $r^2 \geq 0.8$ of the top hit for these loci.

Functional look-ups

For variants identified as part of a credible set, we carried out look-ups in the following functional data resources; (i) regulomeDB and Haploreg were mined for evidence of coding or regulatory function (these resources collate annotations [e.g., coding variation, regulatory chromatin marks, DNase I hypersensitivity, protein binding and motif alteration] from the ENCODE Consortium, the NIH Roadmap Epigenomics Mapping Consortium, and the literature over a wide range of tissues); (ii) cis-eQTL for skin or LCLs were identified from the MuTHER consortium³⁵ (with variants considered eQTLs if association with any transcript within 1Mb was $p < 7 \times 10^{-4}$, corresponding to a bonferroni correction for 36 loci and 2 tissues); (iii) differential expression reported for implicated genes between uninvolved skin from cases and skin from controls⁶⁵ and between lesional and non-lesional skin in atopic dermatitis patients in a study deposited in the Gene Expression Omnibus (Accession=GDS4444)⁶⁶; and (iv) mouse mutants of implicated genes were examined in the MGI database.

Colocalization of atopic dermatitis GWAS signals and eQTLs in the MuTHER data was investigated using the R package coloc⁶⁷. All SNPs within 100kb of the lead atopic dermatitis SNP were included in the analysis and we report the posterior probabilities that the two signals colocalize in Supplementary Table 19.

To identify and visualize cell types implicated in atopic dermatitis pathogenesis, the tendency of disease associated loci to fall in cell-type specific regulatory DNase Hypersensitive Sites (DHS) (a proxy for accessible and/or regulatory DNA) was calculated for the full range of p-values, essentially as done by Maurano *et al.*⁶⁸. This enrichment was

computed for 168 cell types and cell lines in the ENCODE Roadmap repository³⁶. Duplicates and directly redundant cell types were removed before analysis. One-sided p-values for enrichment were calculated from an empirical null distribution of loci overlap for DHS-regions, generated by 10,000 random permutations of overlapping an identical number of random loci as found at $p \leq 1 \times 10^{-10}$ with all DHS-regions for all cell- and tissue types.

Variance in liability explained

We estimated the proportion of variance in atopic dermatitis liability explained by the established and novel variants in a subset of studies that had clinically diagnosed cases (GENEVA/KORAF4/POPGEN, NCRC-ADC, GENUFADex-SHIP1, GENUFAD-SHIP2, GENEVA(replication), CECCS) using the method of So *et al.* (2011)⁶⁹.

Data access

Genome-wide results are available on request to the corresponding author, on condition of signing any Data Transfer Agreements required according the IRB-approved protocols of contributing studies.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Lavinia Paternoster^{#1,2}, Marie Standl^{#3}, Johannes Waage⁴, Hansjörg Baurecht⁵, Melanie Hotze⁵, David P Strachan⁶, John A Curtin⁷, Klaus Bønnelykke⁴, Chao Tian⁸, Atsushi Takahashi⁹, Jorge Esparza-Gordillo^{10,11}, Alexsander Couto Alves¹², Jacob P Thyssen¹³, Herman T den Dekker^{14,15,16}, Manuel A Ferreira¹⁷, Elisabeth Altmaier^{18,19,20}, Patrick MA Sleiman^{21,22}, Feng Li Xiao²³, Juan R Gonzalez²⁴, Ingo Marenholz^{10,11}, Birgit Kalb^{10,25}, Maria Pino Yanes^{26,27,28}, Cheng-Jian Xu^{29,30}, Lisbeth Carstensen³¹, Maria M Groen-Blokhuis³², Cristina Venturini³³, Craig E Pennell³⁴, Sheila J Barton³⁵, Albert M Levin³⁶, Ivan Curjuristic^{37,38}, Mariona Bustamante^{24,39,40,41}, Eskil Kreiner-Møller⁴, Gabrielle A Lockett⁴², Jonas Bacelis⁴³, Supinda Bunyavanich⁴⁴, Rachel A Myers⁴⁵, Anja Matanovic^{10,11}, Ashish Kumar^{37,38,46,47}, Joyce Y Tung⁸, Tomomitsu Hirota⁴⁸, Michiaki Kubo⁴⁹, Wendy L McArdle², A J Henderson², John P Kemp^{1,2,50}, Jie Zheng^{1,2}, George Davey Smith^{1,2}, Franz Rüschenhoff¹⁰, Anja Bauerfeind¹⁰, Min Ae Lee-Kirsch⁵¹, Andreas Arnold⁵², Georg Homuth⁵³, Carsten O Schmidt⁵⁴, Elisabeth Mangold⁵⁵, Sven Cichon^{55,56,57,58,59}, Thomas Keil^{60,61}, Elke Rodríguez⁵, Annette Peters^{19,62}, Andre Franke⁶³, Wolfgang Lieb⁶⁴, Natalija Novak⁶⁵, Regina Fölster-Holst⁵, Momoko Horikoshi⁴⁷, Juha Pekkanen^{66,67}, Sylvain Sebert^{68,69}, Lise L Husemoen⁷⁰, Niels Grarup⁷¹, Johan C de Jongste¹⁴, Fernando Rivadeneira^{15,16,72}, Albert Hofman¹⁵, Vincent WV Jaddoe^{14,15,16}, Suzanne GMA Pasmans⁷³, Niels J Elbert^{16,73}, André G Uitterlinden^{15,72}, Guy B Marks⁷⁴, Philip J Thompson^{75,76}, Melanie C Matheson⁷⁷, Colin F Robertson⁷⁸, Australian Asthma Genetics Consortium (AAGC)⁷⁹, Janina S Ried²⁰, Jin Li²¹, Xian Bo Zuo²³, Xiao Dong Zheng²³, Xian Yong Yin²³, Liang Dan

Sun²³, Maeve A McAleer^{80,81}, Grainne M O'Regan⁸¹, Caoimhe MR Fahy⁸², Linda E Campbell⁸³, Milan Macek⁸⁴, Michael Kurek⁸⁵, Donglei Hu²⁶, Celeste Eng²⁶, Dirkje S Postma²⁹, Bjarke Feenstra³¹, Frank Geller³¹, Jouke Jan Hottenga³², Christel M Middeldorp³², Pirro Hysi³³, Veronique Bataille³³, Tim Spector³³, Carla MT Tiesler^{3,86}, Elisabeth Thiering^{3,86}, Badri Pahukasahasram⁸⁷, James J Yang⁸⁸, Medea Imboden^{37,38}, Scott Huntsman²⁶, Natàlia Vilor-Tejedor^{24,40,41}, Caroline L Relton^{1,89}, Ronny Myhre⁹⁰, Wenche Nystad⁹⁰, Adnan Custovic⁷, Scott T Weiss⁹¹, Deborah A Meyers⁹², Cilla Söderhäll^{93,94}, Erik Melén^{46,95}, Carole Ober⁴⁵, Benjamin A Raby⁹¹, Angela Simpson⁷, Bo Jacobsson^{43,90}, John W Holloway^{42,96}, Hans Bisgaard⁴, Jordi Sunyer^{24,40,41,97}, Nicole M Probst Hensch^{37,38}, L Keoki Williams^{87,98}, Keith M Godfrey^{35,99}, Carol A Wang³⁴, Dorret I Boomsma^{32,100}, Mads Melbye^{31,101,102}, Gerard H Koppelman¹⁰³, Deborah Jarvis^{104,105}, WH Irwin McLean⁸³, Alan D Irvine^{80,81,82}, Xue Jun Zhang²³, Hakon Hakonarson^{21,22}, Christian Gieger^{18,19,20}, Esteban G Burchard^{26,106}, Nicholas G Martin¹⁷, Liesbeth Duijts^{14,15,16}, Allan Linneberg^{70,101,107}, Marjo-Riitta Jarvelin^{69,108,109,110}, Markus M Noethen^{55,56}, Susanne Lau²⁵, Norbert Hübner¹⁰, Young-Ae Lee^{10,11}, Mayumi Tamari⁴⁸, David A Hinds⁸, Daniel Glass³³, Sara J Brown^{83,111}, Joachim Heinrich³, David M Evans^{1,2,50,113}, and Stephan Weidinger^{5,113} **for the EARly Genetics & Lifecourse Epidemiology (EAGLE) eczema consortium**¹¹⁴

Affiliations

¹Medical Research Council (MRC) Integrative Epidemiology Unit, University of Bristol, Bristol, UK. ²School of Social and Community Medicine, University of Bristol, Bristol, UK. ³Institute of Epidemiology I, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany. ⁴Copenhagen Prospective Studies on Asthma in Childhood (COPSAC), Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. ⁵Department of Dermatology, Allergology and Venereology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. ⁶Population Health Research Institute, St George's, University of London, London, UK. ⁷Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester and University Hospital of South Manchester National Health Service (NHS) Foundation Trust, Manchester, United Kingdom. ⁸23andMe, Inc., Mountain View, CA, USA. ⁹Laboratory for Statistical Analysis, Center for Integrative Medical Sciences, Institute of Physical and Chemical Research (RIKEN), Yokohama, Japan. ¹⁰Max-Delbrück-Center (MDC) for Molecular Medicine, Berlin, Germany. ¹¹Clinic for Pediatric Allergy, Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany. ¹²Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. ¹³National Allergy Research Centre, Department of Dermatology and Allergology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. ¹⁴Department of Pediatrics, Erasmus MC, Rotterdam, the Netherlands. ¹⁵Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands. ¹⁶The Generation R Study Group, Erasmus MC, Rotterdam, the Netherlands. ¹⁷QIMR Berghofer Medical Research Institute, Brisbane, Australia. ¹⁸Research Unit of

Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. ¹⁹Institute of Epidemiology II, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany. ²⁰Institute of Genetic Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. ²¹The Center for Applied Genomics, The Children's Hospital of Philadelphia, PA, USA. ²²Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ²³Institute of Dermatology, Anhui Medical University, Hefei, Anhui, China. ²⁴Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain. ²⁵Pediatric Pneumology and Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany. ²⁶Department of Medicine, University of California, San Francisco, CA, USA. ²⁷Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain. ²⁸Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain. ²⁹University of Groningen, University Medical Center Groningen, Department of Pulmonology, Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, the Netherlands. ³⁰University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, the Netherlands. ³¹Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark. ³²Dept Biological Psychology, Netherlands Twin Register, VU University, Amsterdam, the Netherlands. ³³KCL Department of Twin Research and Genetic Epidemiology, King's College London, London, UK. ³⁴School of Women's and Infants' Health, The University of Western Australia (UWA), Perth, Australia. ³⁵Medical Research Council (MRC) Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK. ³⁶Department of Public Health Sciences, Henry Ford Health System, Detroit, MI, USA. ³⁷Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland. ³⁸University of Basel, Basel, Switzerland. ³⁹Centre for Genomic Regulation (CRG), Barcelona, Spain. ⁴⁰Pompeu Fabra University (UPF), Barcelona, Spain. ⁴¹Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. ⁴²Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK. ⁴³Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, Sweden. ⁴⁴Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁴⁵Department of Human Genetics, University of Chicago, Chicago, IL, USA. ⁴⁶Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. ⁴⁷Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. ⁴⁸Laboratory for Respiratory and Allergic Diseases, Center for Integrative Medical Sciences, Institute of Physical and Chemical Research (RIKEN), Yokohama, Japan. ⁴⁹Laboratory for Genotyping Development, Center for Integrative Medical Sciences, Institute of Physical and Chemical Research (RIKEN), Yokohama, Japan. ⁵⁰University of Queensland

Diamantina Institute, Translational Research Institute, University of Queensland, Brisbane, Australia. ⁵¹Klinik für Kinder- und Jugendmedizin, Technical University Dresden, Dresden, Germany. ⁵²Clinic and Polyclinic of Dermatology, University Medicine Greifswald, Greifswald, Germany. ⁵³Department of Functional Genomics, Interfaculty Institute for Genetics and Functional Genomics, University Medicine and Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany. ⁵⁴Institute for Community Medicine, Study of Health in Pomerania/KEF, University Medicine Greifswald, Greifswald, Germany. ⁵⁵Institute of Human Genetics, University of Bonn, Bonn, Germany. ⁵⁶Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany. ⁵⁷Division of Medical Genetics, University Hospital Basel, Basel, Switzerland. ⁵⁸Department of Biomedicine, University of Basel, Basel, Switzerland. ⁵⁹Institute of Neuroscience and Medicine (INM-1), Structural and Functional Organisation of the Brain, Genomic Imaging, Research Centre Jülich, Jülich, Germany. ⁶⁰Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany. ⁶¹Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany. ⁶²Deutsches Forschungszentrum für Herz-Kreislaufkrankungen (DZHK) (German Research Centre for Cardiovascular Research), Munich Heart Alliance, Munich, Germany. ⁶³Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany. ⁶⁴Institute of Epidemiology, Christian-Albrechts University Kiel, Kiel, Germany. ⁶⁵Department of Dermatology and Allergy, University of Bonn Medical Center, Bonn, Germany. ⁶⁶Unit of Living Environment and Health, National Institute for Health and Welfare, Kuopio, Finland. ⁶⁷Department of Public Health, University of Helsinki, Helsinki, Finland. ⁶⁸Center for Life-course and Systems Epidemiology, Faculty of Medicine, University of Oulu, Finland. ⁶⁹Biocenter Oulu, University of Oulu, Finland. ⁷⁰Research Centre for Prevention and Health, Capital Region of Denmark, Copenhagen, Denmark. ⁷¹The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ⁷²Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands. ⁷³Department of Dermatology, Erasmus MC, Rotterdam, the Netherlands. ⁷⁴Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia. ⁷⁵Lung Institute of Western Australia, QE II Medical Centre Nedlands, Western Australia, Australia. ⁷⁶School of Medicine and Pharmacology, University of Western Australia, Perth, Australia. ⁷⁷Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia. ⁷⁸Murdoch Children's Research Institute, Melbourne, Australia. ⁷⁹A full list of consortium members is provided in Supplementary Note 1, page 4. ⁸⁰National Children's Research Centre, Crumlin, Dublin, Ireland. ⁸¹Our Lady's Children's Hospital, Crumlin, Dublin, Ireland. ⁸²Clinical Medicine, Trinity College Dublin, Dublin, Ireland. ⁸³Centre for Dermatology and Genetic Medicine, University of Dundee, Dundee, UK. ⁸⁴Department of Biology and Medical Genetics, University Hospital Motol and 2nd Faculty of Medicine of Charles University, Prague, Czech Republic. ⁸⁵Department of Clinical Allergology, Pomeranian, Pomeranian Medical University, Szczecin, Poland. ⁸⁶Ludwig-Maximilians-University of Munich,

Dr. von Hauner Children's Hospital, Division of Metabolic Diseases and Nutritional Medicine, Munich, Germany. ⁸⁷Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, MI, USA. ⁸⁸School of Nursing, University of Michigan, Ann Arbor, MI, USA. ⁸⁹Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK. ⁹⁰Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway. ⁹¹Channing Division of Network Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA. ⁹²Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, USA. ⁹³Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden. ⁹⁴Center for Innovative Medicine (CIMED), Karolinska Institutet, Stockholm, Sweden. ⁹⁵Sachs' Children's Hospital, Stockholm, Sweden. ⁹⁶Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. ⁹⁷Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. ⁹⁸Department of Internal Medicine, Henry Ford Health System, Detroit, MI, USA. ⁹⁹National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service (NHS) Foundation Trust, Southampton, UK. ¹⁰⁰Institute for Health and Care Research (EMGO), VU University, Amsterdam, the Netherlands. ¹⁰¹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ¹⁰²Department of Medicine, Stanford School of Medicine, Stanford, California, USA. ¹⁰³University of Groningen, University Medical Center Groningen, Beatrix Children's Hospital, Department of Pediatric Pulmonology and Pediatric Allergology, Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, the Netherlands. ¹⁰⁴Respiratory Epidemiology, Occupational Medicine and Public Health; National Heart and Lung Institute; Imperial College; London, UK. ¹⁰⁵Medical Research Council-Public Health England Centre for Environment and Health, School of Public Health, Imperial College London, London, UK. ¹⁰⁶Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA. ¹⁰⁷Department of Clinical Experimental Research, Rigshospitalet, Glostrup, Denmark. ¹⁰⁸Department of Epidemiology and Biostatistics, Medical Research Council (MRC) Health Protection Agency (HPE) Centre for Environment and Health, School of Public Health, Imperial College London, London, UK. ¹⁰⁹Center for Life Course Epidemiology, Faculty of Medicine, University of Oulu, Oulu, Finland. ¹¹⁰Unit of Primary Care, Oulu University Hospital, Oulu, Finland. ¹¹¹Department of Dermatology, Ninewells Hospital and Medical School, Dundee, UK. ¹¹³These authors jointly directed this work. ¹¹⁴All authors.

Acknowledgements

This publication is the work of the authors and Lavinia Paternoster will serve as guarantor for the contents of this paper. This research was specifically funded by an MRC Population Health Scientist Fellowship awarded to Dr L Paternoster (MR/J012165/1). D.M.E. is supported by an Australian Research Council Future Fellowship (FT130101709) and a Medical Research Council program grant (MC_UU_12013/4). Individual study acknowledgement and funding statements can be found in the Supplementary material.

Author Contributions

Conceived and designed the experiments: L.P., M.S., H. Baurecht, D.P.S., J.A.C., K.B., J.P.T., H.T.d.D., P.M.A.S., F.L.X., M.B., J.Y.T., A.J.H., G.D.S., E.R., J.P., L.L.H., J.C.d.J., F. Rivadeneira, A.H., V.W.V.J., S.G.M.A.P., N.J.E., A.G.U., D.S.P., B.F., A.C., D.A.M., E. Melén, C.O., A.S., B.J., J.W.H., H. Bisgaard, J.S., N.M.P.H., L.K.W., K.M.G., D.I.B., M. Melbye, G.H.K., Y.A.L., N.H., D.J., X.J.Z., H.H., L.D., A.L., M.R.J., M.T., S.J. Brown, J.H., D.M.E., S.W.

Performed the experiments: L.P., K.B., P.M.A.S., F.L.X., M.B., E.K.M., G.A.L., M. Kubo, W.L.M., J.P.K., J.Z., E.R., F. Rivadeneira, A.G.U., J.L., X.Y.Y., L.D.S., L.E.C., A.M., C.E., D.S.P., C.M.T.T., M.I., S.H., N.V.T., B.J., H. Bisgaard, N.M.P.H., L.K.W., K.M.G., G.H.K., A.L., S.J. Brown, D.M.E., S.W.

Performed the statistical analysis: L.P., M.S., J.W., H. Baurecht, M. Hotze, D.P.S., J.A.C., C.T., A.T., A.B., A.C.A., H.T.d.D., M.A.F., E.A., P.M.A.S., J.R.G., I.M., J.E.G., M.P.Y., C.J.X., L.C., M.M.G.B., C.V., S.J. Barton, A.M.L., I.C., E.K.M., G.A.L., S.B., R.A.M., F. Rüschenhoff, A.K., J.P.K., J.Z., L.L.H., F. Rivadeneira, N.J.E., J.R., J.L., X.B.Z., X.D.Z., D.H., B.F., F.G., P.H., C.M.T.T., E.T., B.P., J.J.Y., N.V.T., R.M., C.A.W., L.D., D.A.H., D.M.E.

Analysed the data: L.P., M.S., J.W., H. Baurecht, M. Hotze, D.P.S., J.A.C., K.B., C.T., A.B., A.C.A., J.P.T., H.T.d.D., M.A.F., E.A., P.M.A.S., F.L.X., J.R.G., I.M., J.E.G., M.P.Y., C.J.X., L.C., M.M.G.B., C.V., S.J. Barton, A.M.L., I.C., G.A.L., J.B., S.B., R.A.M., F. Rüschenhoff, A.K., A.J.H., M. Horikoshi, S.S., L.L.H., F. Rivadeneira, N.J.E., A.G.U., M.C.M., J.R., J.L., X.B.Z., X.D.Z., X.Y.Y., D.H., B.F., F.G., J.J.H., C.M.M., P.H., C.M.T.T., E.T., B.P., J.J.Y., M.I., S.H., N.V.T., E. Melén, B.J., L.K.W., C.A.W., Y.A.L., N.H., L.D., A.L., M.T., D.A.H., D.G., S.J. Brown, D.M.E.

Contributed reagents/material/analysis tools: L.P., J.W., H. Baurecht, M. Hotze, C.T., H.T.d.D., P.M.A.S., M.P.Y., C.E.P., A.M.L., M.B., S.B., T.H., M. Kubo, W.L.M., J.Z., G.D.S., M. Macek, M. Kurek, M.A.L.K., E. Mangold, A.P., A.F., W.L., N.N., R.F.H., N.G., J.C.d.J., F. Rivadeneira, A.H., V.W.V.J., S.G.M.A.P., N.J.E., A.G.U., G.B.M., P.J.T., C.F.R., NA, J.L., L.D.S., M.A.M., G.M.O., C.M.R.F., A.A., G.H., C.O.S., B.K., D.H., C.E., D.S.P., V.B., T.S., B.P., J.J.Y., C.L.R., S.T.W., D.A.M., S.C., T.K., C.S., E. Melén, S.L., C.O., B.A.R., B.J., J.W.H., J.S., L.K.W., K.M.G., M. Melbye, G.H.K., Y.A.L., N.H., D.J., W.H.I.M., A.D.I., X.J.Z., H.H., C.G., E.G.B., N.G.M., L.D., M.R.J., M.M.N., M.T., D.A.H., S.J. Brown, J.H., S.W.

Wrote the paper: L.P., M.S., J.W., H. Baurecht, M. Hotze, D.P.S., J.A.C., K.B., A.J.H., S.J. Brown, D.M.E., S.W.

Revising and reviewing paper: L.P., M.S., J.W., H. Baurecht, M. Hotze, D.P.S., J.A.C., K.B., C.T., A.T., A.B., A.C.A., J.P.T., H.T.d.D., M.A.F., E.A., P.M.A.S., F.L.X., J.R.G., I.M., J.E.G., M.P.Y., C.J.X., L.C., M.M.G.B., C.V., C.E.P., S.J. Barton, A.M.L., I.C., M.B., E.K.M., G.A.L., S.B., R.A.M., F. Rüschenhoff, A.K., J.Y.T., T.H., M. Kubo, W.L.M., A.J.H., J.P.K., J.Z., G.D.S., M. Macek, M. Kurek, M.A.L.K., E. Mangold, E.R., A.P., A.F., W.L.,

N.N., R.F.H., M. Horikoshi, J.P., S.S., L.L.H., N.G., J.C.d.J., F. Rivadeneira, A.H., V.W.V.J., S.G.M.A.P., N.J.E., A.G.U., G.B.M., P.J.T., M.C.M., C.F.R., J.R., J.L., X.B.Z., X.D.Z., X.Y.Y., L.D.S., M.A.M., G.M.O., C.M.R.F., L.E.C., A.A., G.H., A.M., C.O.S., B.K., D.H., C.E., D.S.P., B.F., F.G., J.J.H., C.M.M., P.H., V.B., T.S., C.M.T.T., E.T., B.P., J.J.Y., M.I., S.H., N.V.T., C.L.R., R.M., W.N., A.C., S.T.W., D.A.M., S.C., T.K., C.S., E. Melén, S.L., C.O., B.A.R., A.S., B.J., J.W.H., H. Bisgaard, J.S., N.M.P.H., L.K.W., K.M.G., C.A.W., D.I.B., M. Melbye, G.H.K., Y.A.L., N.H., D.J., W.H.I.M., A.D.I., X.J.Z., H.H., C.G., E.G.B., N.G.M., L.D., A.L., M.R.J., M.M.N., M.T., D.A.H., D.G., S.J. Brown, J.H., D.M.E., S.W.

AAGC provided results for the discovery analysis.

References

1. Bieber T. Atopic dermatitis. *New Engl J Med.* 2008; 358:1483–94. [PubMed: 18385500]
2. Bataille V, Lens M, Spector TD. The use of the twin model to investigate the genetics and epigenetics of skin diseases with genomic, transcriptomic and methylation data. *J Eur Acad Dermatol Venereol.* 2012; 26:1067–73. [PubMed: 22243446]
3. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. *N Engl J Med.* 2011; 365:1315–27. [PubMed: 21991953]
4. Palmer CNA, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nature genetics.* 2006; 38:441–6. [PubMed: 16550169]
5. Rodriguez E, et al. Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. *J Allergy Clin Immunol.* 2009; 123:1361–70. e7. [PubMed: 19501237]
6. Weidinger S, et al. A genome-wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis. *Hum Mol Genet.* 2013; 22:4841–56. [PubMed: 23886662]
7. Ellinghaus D, et al. High-density genotyping study identifies four new susceptibility loci for atopic dermatitis. *Nat Genet.* 2013; 45:808–12. [PubMed: 23727859]
8. Hirota T, et al. Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population. *Nat Genet.* 2012; 44:1222–6. [PubMed: 23042114]
9. Paternoster L, et al. Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. *Nature genetics.* 2011; 44:187–192. [PubMed: 22197932]
10. Sun L-D, et al. Genome-wide association study identifies two new susceptibility loci for atopic dermatitis in the Chinese Han population. *Nature genetics.* 2011; 43:690–4. [PubMed: 21666691]
11. Esparza-Gordillo J, et al. A common variant on chromosome 11q13 is associated with atopic dermatitis. *Nature genetics.* 2009; 41:596–601. [PubMed: 19349984]
12. Esparza-Gordillo J, et al. A functional IL-6 receptor (IL6R) variant is a risk factor for persistent atopic dermatitis. *J Allergy Clin Immunol.* 2013; 132:371–7. [PubMed: 23582566]
13. Agarwala V, Flannick J, Sunyaev S, Go TDC, Altshuler D. Evaluating empirical bounds on complex disease genetic architecture. *Nat Genet.* 2013; 45:1418–27. [PubMed: 24141362]
14. Hinds DA, et al. A genome-wide association meta-analysis of self-reported allergy identifies shared and allergy-specific susceptibility loci. *Nat Genet.* 2013; 45:907–11. [PubMed: 23817569]
15. Ferreira MAR, et al. Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. *Lancet.* 2011; 378:1006–14. [PubMed: 21907864]
16. Himes B, et al. Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene. *The American Journal of Human Genetics.* 2009; 84:581–593. [PubMed: 19426955]
17. Noguchi E, et al. Genome-wide association study identifies HLA-DP as a susceptibility gene for pediatric asthma in Asian populations. *PLoS Genet.* 2011; 7:e1002170. [PubMed: 21814517]
18. Moffatt MF, et al. A large-scale, consortium-based genomewide association study of asthma. *N Engl J Med.* 2010; 363:1211–21. [PubMed: 20860503]

19. Sleiman PM, et al. Variants of DENND1B associated with asthma in children. *N Engl J Med*. 2010; 362:36–44. [PubMed: 20032318]
20. Hirota T, et al. Genome-wide association study identifies three new susceptibility loci for adult asthma in the Japanese population. *Nature genetics*. 2011; 43:893–6. [PubMed: 21804548]
21. Bonnelykke K, et al. Meta-analysis of genome-wide association studies identifies ten loci influencing allergic sensitization. *Nat Genet*. 2013; 45:902–6. [PubMed: 23817571]
22. Jostins L, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature*. 2012; 491:119–24. [PubMed: 23128233]
23. Tsoi LC, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. *Nat Genet*. 2012; 44:1341–8. [PubMed: 23143594]
24. International Genetics of Ankylosing Spondylitis Consortium. et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. *Nat Genet*. 2013; 45:730–8. [PubMed: 23749187]
25. International Multiple Sclerosis Genetics Consortium. et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. *Nature*. 2011; 476:214–9. [PubMed: 21833088]
26. Okada Y, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature*. 2014; 506:376–81. [PubMed: 24390342]
27. Bradfield JP, et al. A genome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci. *PLoS Genet*. 2011; 7:e1002293. [PubMed: 21980299]
28. Niwa Y, Sumi H, Akamatsu H. An association between ulcerative colitis and atopic dermatitis, diseases of impaired superficial barriers. *J Invest Dermatol*. 2004; 123:999–1000. [PubMed: 15482492]
29. Jakobsen C, Pærrgaard A, Munkholm P, Wewer V. Environmental factors and risk of developing paediatric inflammatory bowel disease -- a population based study 2007-2009. *J Crohns Colitis*. 2013; 7:79–88. [PubMed: 22748696]
30. Baron S, et al. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. *Gut*. 2005; 54:357–63. [PubMed: 15710983]
31. Henseler T, Christophers E. Disease concomitance in psoriasis. *J Am Acad Dermatol*. 1995; 32:982–6. [PubMed: 7751469]
32. Baurecht H, et al. Genome-wide Comparative Analysis of Atopic Dermatitis and Psoriasis Gives Insight into Opposing Genetic Mechanisms. *Am J Hum Genet*. 2015; 96:104–20. [PubMed: 25574825]
33. Segre AV, et al. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. *PLoS Genet*. 2010; 6
34. Wellcome Trust Case Control Consortium. et al. Bayesian refinement of association signals for 14 loci in 3 common diseases. *Nat Genet*. 2012; 44:1294–301. [PubMed: 23104008]
35. Grundberg E, et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. *Nat Genet*. 2012; 44:1084–9. [PubMed: 22941192]
36. Encode Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature*. 2012; 489:57–74. [PubMed: 22955616]
37. Bernstein BE, et al. The NIH Roadmap Epigenomics Mapping Consortium. *Nat Biotechnol*. 2010; 28:1045–8. [PubMed: 20944595]
38. Malissen B, Tamoutounour S, Henri S. The origins and functions of dendritic cells and macrophages in the skin. *Nat Rev Immunol*. 2014; 14:417–28. [PubMed: 24854591]
39. de Jong MA, Geijtenbeek TB. Langerhans cells in innate defense against pathogens. *Trends Immunol*. 2010; 31:452–9. [PubMed: 21030306]
40. Baker BS. The role of microorganisms in atopic dermatitis. *Clin Exp Immunol*. 2006; 144:1–9. [PubMed: 16542358]
41. Tang TS, Bieber T, Williams HC. Does “autoreactivity” play a role in atopic dermatitis? *J Allergy Clin Immunol*. 2012; 129:1209–1215. e2. [PubMed: 22409986]
42. Kitabatake M, et al. Transgenic overexpression of G5PR that is normally augmented in centrocytes impairs the enrichment of high-affinity antigen-specific B cells, increases peritoneal B-1a cells,

- and induces autoimmunity in aged female mice. *J Immunol.* 2012; 189:1193–201. [PubMed: 22753944]
43. Lundstrom W, Fewkes NM, Mackall CL. IL-7 in human health and disease. *Semin Immunol.* 2012; 24:218–24. [PubMed: 22410365]
 44. Gregory SG, et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. *Nat Genet.* 2007; 39:1083–91. [PubMed: 17660817]
 45. Lundmark F, et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. *Nat Genet.* 2007; 39:1108–13. [PubMed: 17660816]
 46. Lundstrom W, et al. Soluble IL7Ralpha potentiates IL-7 bioactivity and promotes autoimmunity. *Proc Natl Acad Sci U S A.* 2013; 110:E1761–70. [PubMed: 23610432]
 47. Uehira M, Matsuda H, Nakamura A, Nishimoto H. Immunologic abnormalities exhibited in IL-7 transgenic mice with dermatitis. *J Invest Dermatol.* 1998; 110:740–5. [PubMed: 9579538]
 48. Steward-Tharp SM, et al. A mouse model of HIES reveals pro- and anti-inflammatory functions of STAT3. *Blood.* 2014; 123:2978–87. [PubMed: 24632714]
 49. Milner JD, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. *Nature.* 2008; 452:773–6. [PubMed: 18337720]
 50. Lupski JR, Belmont JW, Boerwinkle E, Gibbs RA. Clan genomics and the complex architecture of human disease. *Cell.* 2011; 147:32–43. [PubMed: 21962505]
 51. Blair DR, et al. A nondegenerate code of deleterious variants in Mendelian loci contributes to complex disease risk. *Cell.* 2013; 155:70–80. [PubMed: 24074861]
 52. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. *Cancer Res.* 2007; 67:11001–11. [PubMed: 18006846]
 53. Ferreira MA, et al. Genome-wide association analysis identifies 11 risk variants associated with the asthma with hay fever phenotype. *J Allergy Clin Immunol.* 2014; 133:1564–71. [PubMed: 24388013]
 54. Sritesky GL, Jameson SC, Hogquist KA. Selection of self-reactive T cells in the thymus. *Annu Rev Immunol.* 2012; 30:95–114. [PubMed: 22149933]
 55. Moisan J, Grenningloh R, Bettelli E, Oukka M, Ho IC. Ets-1 is a negative regulator of Th17 differentiation. *J Exp Med.* 2007; 204:2825–35. [PubMed: 17967903]
 56. Nagarajan P, et al. Ets1 blocks terminal differentiation of keratinocytes and induces expression of matrix metalloproteases and innate immune mediators. *J Cell Sci.* 2010; 123:3566–75. [PubMed: 20930145]
 57. Beck LA, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. *N Engl J Med.* 2014; 371:130–9. [PubMed: 25006719]
 58. Granada M, et al. A genome-wide association study of plasma total IgE concentrations in the Framingham Heart Study. *J Allergy Clin Immunol.* 2012; 129:840–845. e21. [PubMed: 22075330]
 59. Ramasamy A, et al. A genome-wide meta-analysis of genetic variants associated with allergic rhinitis and grass sensitization and their interaction with birth order. *J Allergy Clin Immunol.* 2011; 128:996–1005. [PubMed: 22036096]

Methods-only references

60. Morris AP. Transethnic meta-analysis of genomewide association studies. *Genet Epidemiol.* 2011; 35:809–22. [PubMed: 22125221]
61. Wang X, et al. Comparing methods for performing trans-ethnic meta-analysis of genome-wide association studies. *Hum Mol Genet.* 2013; 22:2303–11. [PubMed: 23406875]
62. Yang J, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Genet.* 2012; 44:369–75. S1–3. [PubMed: 22426310]
63. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. *Am J Hum Genet.* 2004; 74:765–9. [PubMed: 14997420]

64. Welter D, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res.* 2014; 42:D1001–6. [PubMed: 24316577]
65. Cole C, et al. Filaggrin-stratified transcriptomic analysis of pediatric skin identifies mechanistic pathways in patients with atopic dermatitis. *J Allergy Clin Immunol.* 2014; 134:82–91. [PubMed: 24880632]
66. Tintle S, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. *J Allergy Clin Immunol.* 2011; 128:583–93. e1–4. [PubMed: 21762976]
67. Giambartolomei C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet.* 2014; 10:e1004383. [PubMed: 24830394]
68. Maurano MT, et al. Systematic localization of common disease-associated variation in regulatory DNA. *Science.* 2012; 337:1190–5. [PubMed: 22955828]
69. So HC, Li M, Sham PC. Uncovering the total heritability explained by all true susceptibility variants in a genome-wide association study. *Genet Epidemiol.* 2011; 35:447–56. [PubMed: 21618601]




Figure 1. Atopic dermatitis GWAS meta-analysis results
 (A) Manhattan plot of European fixed effects meta-analysis. (B) Manhattan plot of the multi-ethnic MANTRA meta-analysis of all studies. Arrows mark variants not associated in the European-only analysis. (C) QQ plot of the European analysis - lambda=1.054.

Table 1

Discovery Results. The index variant for loci with $p < 5 \times 10^{-8}$ in the European analysis or $\log_{10}BF > 6.1$ in the multi-ethnic MANTRA analysis. Previous atopy trait associations with these loci are listed.

Variant	Locus	Nearest Gene [‡]	EA/OA	N (studies)	EAF	OR (95% CI)	European – fixed effects		All cohorts – MANTRA		Known atopy loci?	references
							N (studies)	P-value	N (studies)	log ₁₀ BF		
KNOWN LOCI												
rs61813875	1q21.3	CRCT1/LCE3E (FLG) [§]	G/C	93,326 (18)	0.02	1.61 (1.48–1.75)	5.6×10^{-29}	96,419 (20)	25.53	AD	3,4,5	
rs10791824	11q13.1	OVOL1	G/A	102,761 (21)	0.57	1.12 (1.09–1.15)	2.1×10^{-19}	116,556 (25)	21.56	AD	9	
rs12188917	5q31.1	RADS0/IL13	C/T	102,761 (21)	0.21	1.14 (1.10–1.17)	4.0×10^{-17}	116,554 (25)	17.24	AD, A, IgE	9,18,58	
rs6419573	2q12.1	IL18R1/IL18RAP	T/C	102,760 (21)	0.26	1.11 (1.08–1.14)	1.5×10^{-13}	116,557 (25)	18.10	AD, A, AS, SRA	8,14,18,21	
rs2212434	11q13.5	C11orf50/LRRC32	T/C	102,761 (21)	0.45	1.09 (1.07–1.12)	4.6×10^{-13}	116,557 (25)	13.02	AD, AS, SRA, AR, A	11,14,15,21,59	
rs4809219	20q13.33	RTEL1-TNFRSF6B	C/A	102,760 (21)	0.27	0.90 (0.87–0.93)	7.0×10^{-13}	116,555 (25)	11.98	AD	7,10	
rs2918307	19p13.2	ADAMTS10/ACTL9	G/A	100,707 (20)	0.16	1.12 (1.08–1.16)	4.6×10^{-12}	114,504 (24)	12.98	AD	9	
rs2041733	16p13.13	CLEC16A	C/T	103,066 (22)	0.55	0.92 (0.90–0.94)	2.5×10^{-11}	116,862 (26)	10.11	AD, A+HF	7,53	
rs12730935*	1q21.3	IL6R	A/G	102,760 (21)	0.39	1.08 (1.05–1.11)	6.1×10^{-11}	116,556 (25)	7.15	AD, A	12,15	
4:123245592 [†]	4q27	KIAA109 (IL2) [§]	R/T	102,761 (21)	0.37	1.08 (1.05–1.10)	4.2×10^{-9}	107,119 (24)	7.32	AD, AS, SRA	7,14,21	
rs4713555	6p21.32	HLA-DRB1/HLA-DQA1	T/G	91,217 (15)	0.27	0.91 (0.89–0.94)	5.4×10^{-9}	105,014 (19)	10.76	AD, AS, SRA, A	6,8,14,18,21	
rs2944542	10q21.2	ZNF365	C/G	102,762 (21)	0.41	0.94 (0.92–0.96)	1.2×10^{-6}	116,559 (25)	7.56	AD	8,10	
rs145809981	6p21.33	MICB	T/C	97,697 (19)	0.14	0.91 (0.88–0.95)	1.5×10^{-6}	110,228 (22)	7.33	AD, AS, SRA	8,14,21	
rs4312054	11p15.4	OR10A3/NLRP10	G/T	102,760 (21)	0.41	1.00 (0.97–1.02)	0.744	116,556 (25)	7.00	AD	8	
rs1249910	3q13.2	CCDC80/CD200R1L	A/G	99,164 (20)	0.34	0.98 (0.96–1.01)	0.137	112,960 (24)	6.86	AD	8	
rs2522555	1p13	PRRS1	C/T	102,760 (21)	0.27	0.93 (0.90–0.96)	8.7×10^{-7}	116,551 (25)	6.78	AD	7	
NOVEL LOCI												
rs2038255	14q13.2	PPP2R3C	T/C	102,760 (21)	0.18	1.11 (1.07–1.14)	1.8×10^{-10}	116,557 (25)	8.40			
rs7127307	11q24.3	-ETS1	C/T	103,066 (22)	0.47	0.93 (0.90–0.95)	3.9×10^{-10}	116,855 (26)	9.08	SRA	14	
rs7512552	1q21.2	C1orf51/MRPS21	T/C	102,762 (21)	0.49	0.93 (0.91–0.95)	9.1×10^{-10}	116,544 (25)	6.91			
rs6473227	8q21.13	MIR5708/ZBTB10	A/C	102,761 (21)	0.61	0.93 (0.91–0.95)	1.4×10^{-9}	116,557 (25)	7.54	(AD), SRA, A+HF	9,14,53	
rs6602364	10p15.1	IL15RA/IL2RA	G/C	103,065 (22)	0.45	1.08 (1.05–1.10)	1.5×10^{-9}	116,855 (26)	7.86	(SRA)	14	

Variant	Locus	Nearest Gene [‡]	EA/OA	European – fixed effects				All cohorts – MANTRA		Known atopy loci?	
				N (studies)	EAF	OR (95% CI)	P-value	N (studies)	log ₁₀ BF	trait	references
rs10214237	5p13.2	IL7R/CAPSL	C/T	102,761 (21)	0.27	0.93 (0.90–0.95)	2.9 ×10 ⁻⁸	116,554 (25)	4.79		
rs10199605	2p25.1	LINC00299/-	A/G	102,760 (21)	0.30	0.93 (0.90–0.95)	3.4 ×10 ⁻⁸	116,557 (25)	4.67	(SRA)	14
rs4643526	2p16.1	PUS10	A/G	103,066 (22)	0.19	1.09 (1.06–1.12)	3.5 ×10 ⁻⁸	107,425 (25)	6.31		
rs12951971	17q21.2	STAT3	G/T	102,761 (21)	0.09	1.13 (1.08–1.17)	4.1 ×10 ⁻⁸	107,120 (24)	5.33		
rs7625909	3p21.1	SFMBT1/RFT1	T/C	102,761 (21)	0.32	1.07 (1.05–1.10)	4.9 ×10 ⁻⁸	116,558 (25)	5.83		
rs11211458	2p13.3	CD207/VA X2	G/A	102,760 (21)	0.13	0.91 (0.87–0.94)	1.4×10 ⁻⁷	116,553 (25)	6.57		

* in LD with known functional mutation rs2228145 ($r^2=0.86$)

[†] nearby SNP (rs6827756, bp position: 123184411) in LD ($r^2=0.97$ in 1000genomes) showed similar association, log₁₀BF=7.21, European fixed effects p-value 3×10^{-9}

[‡] Nearest genes are the two flanking genes if intergenic (with the closer gene in **bold**, - indicates no gene within 250kb), single genes denote the variant is intronic.

[§] at 1q21.2: variant is closest to LCE3A, but previously associated FLG is within 250kb, at 4q27: variant is within an intron of KIAA109, but previously associated IL2 is within 150kb, AD= atopic dermatitis, A=asthma, AS=allergic sensitization, SRA=self-reported allergy, AR=allergic rhinitis, A+HF=asthma and hayfever combined,

P-values and $-\log_{10}$ Bayes Factors (BF) in **bold** indicate genome-wide significant results

EA/OA= effect allele/other allele, EAF = effect allele frequency, OR=odds ratio, CI=confidence interval, N= sample size, BF= bayes factor

Table 2
Replication results for the novel genome-wide significant loci and loci identified in the MAGENTA gene-set enrichment analysis. Discovery, replication and combined results are shown.

Variant	Locus	Nearest Gene	EAV/OA	EAF	N (studies)	Discovery European			Replication European			Overall European - fixed effects			het		random effects p-values European	all studies
						OR (95% CI)	P-value	N (studies)	OR (95% CI)	P-value	N	OR (95% CI)	P-value	N	P-value	p-value		
NOVEL GENOMEWIDE SIGNIFICANT LOCI																		
rs7512552	1q21.2	C1orf51/MRPS21	T/C	0.49	102762 (21)	0.93(0.91-0.95)	9.1×10 ⁻¹⁰	257019 (15)	0.98(0.96-0.99)	0.0048	359781	0.96(0.94-0.97)	5.41×10 ⁻⁹	0.002	1.5×10 ⁻⁷	1.3×10 ⁻⁷		
rs10919605	2p25.1	LINC00299/-	A/G	0.30	102760 (21)	0.93(0.90-0.95)	3.4×10 ⁻⁸	256958 (15)	0.97(0.95-0.99)	0.0045	359718	0.96(0.94-0.97)	3.97×10 ⁻⁸	0.024	4.1×10 ⁻⁶	1.5×10 ⁻⁵		
rs643526	2p16.1	PUS10	A/G	0.19	103066 (22)	1.09(1.06-1.12)	3.5×10 ⁻⁸	257050 (14)	1.03(1.01-1.05)	0.0058	360116	1.05(1.03-1.07)	5.94×10 ⁻⁸	0.249	3.8×10 ⁻⁶	1.1×10 ⁻⁵		
rs11211458	2p13.3	CD207/VAX2	G/A	0.13	102760 (21)	0.91(0.87-0.94)	1.4×10 ⁻⁷	257019 (15)	0.95(0.93-0.98)	7.95×10 ⁻⁴	359779	0.94(0.92-0.96)	9.38×10 ⁻⁹	0.076	4.4×10 ⁻⁶	1.6×10 ⁻⁷		
rs11923593*	3p21.1	SEMBL1/RF11	G/A	0.32	102761 (21)	1.07(1.04-1.10)	9.7×10 ⁻⁸	257002 (15)	1.01(0.99-1.03)	0.2600	359763	1.03(1.01-1.05)	1.30×10 ⁻⁴	0.081	8.7×10 ⁻⁵	1.7×10 ⁻⁵		
rs10214237	5p13.2	ILTR/CAPSL	C/T	0.27	102761 (21)	0.93(0.90-0.95)	2.9×10 ⁻⁸	257010 (15)	0.94(0.93-0.96)	6.71×10 ⁻⁸	359771	0.94(0.92-0.95)	2.86×10 ⁻¹⁴	0.773	2.9×10 ⁻¹⁴	1.5×10 ⁻¹⁰		
rs6473227	8q21.13	MIR5708/ZBTB10	A/C	0.61	102761 (21)	0.93(0.91-0.95)	1.4×10 ⁻⁹	257006 (15)	0.95(0.93-0.97)	4.53×10 ⁻⁹	359767	0.94(0.93-0.95)	2.22×10 ⁻¹⁶	0.622	2.2×10 ⁻¹⁶	5.3×10 ⁻¹⁸		
rs6602564	10p15.1	IL15RA/IL2RA	G/C	0.45	103065 (22)	1.08(1.05-1.10)	1.5×10 ⁻⁹	256993 (15)	1.03(1.01-1.05)	3.91×10 ⁻⁴	360058	1.05(1.03-1.06)	1.33×10 ⁻¹⁰	0.041	3.6×10 ⁻⁶	1.6×10 ⁻⁶		
rs7127307	11q24.3	-ETS1	C/T	0.47	103066 (22)	0.93(0.90-0.95)	3.9×10 ⁻⁹	257034 (15)	0.94(0.93-0.96)	2.51×10 ⁻¹⁰	360100	0.94(0.92-0.95)	1.48×10 ⁻¹⁸	0.935	1.5×10 ⁻¹⁸	1.0×10 ⁻²⁰		
rs2143950*	14q13.2	PPP2R3C	T/C	0.17	102762 (21)	1.10(1.07-1.14)	6.8×10 ⁻¹⁰	249940 (12)	1.07(1.04-1.09)	9.92×10 ⁻⁸	352702	1.08(1.06-1.10)	1.78×10 ⁻¹⁵	0.092	4.8×10 ⁻⁷	8.6×10 ⁻¹⁰		
rs17881320*	17q21.2	STAT3	T/G	0.08	96796 (19)	1.12(1.07-1.17)	2.0×10 ⁻⁶	249949 (12)	1.05(1.02-1.09)	1.47×10 ⁻³	346745	1.08(1.05-1.11)	1.41×10 ⁻⁷	0.405	6.2×10 ⁻⁷	2.6×10 ⁻⁶		
MAGENTA GENE-SET ENRICHMENT ANALYSIS LOCI																		
rs1057258	2q37.1	INPP5D	T/C	0.18	101012 (21)	0.94(0.91-0.97)	6.57×10 ⁻⁵	257030 (15)	0.94(0.92-0.96)	3.79×10 ⁻⁷	358042	0.94(0.92-0.96)	1.72×10 ⁻¹⁰	0.811	1.7×10 ⁻¹⁰	4.1×10 ⁻¹³		
rs6872156	5q35.1	DUSP1	A/G	0.24	103066 (22)	0.93(0.91-0.96)	2.35×10 ⁻⁶	257047 (15)	0.97(0.95-0.99)	0.0055	360113	0.96(0.94-0.97)	8.08×10 ⁻⁷	0.340	1.8×10 ⁻⁶	2.7×10 ⁻⁷		
rs7016497	8q24.3	PTK2	T/C	0.21	103066 (22)	0.94(0.91-0.97)	1.09×10 ⁻⁴	257040 (15)	0.98(0.95-1.00)	0.0290	360106	0.96(0.95-0.98)	9.37×10 ⁻⁵	0.757	9.4×10 ⁻⁵	1.4×10 ⁻⁶		
rs2905493	11q12.2	CD6/CD5	T/C	0.01	89617 (15)	0.78(0.68-0.89)	2.63×10 ⁻⁴	254992 (13)	1.01(0.94-1.08)	0.6040	344609	0.95(0.90-1.02)	0.1432	0.150	0.419	0.098		
rs1799986	12q13.3	LRP1(STAT6) [†]	T/C	0.15	99165 (20)	0.91(0.88-0.94)	1.14×10 ⁻⁷	257022 (15)	0.98(0.96-1.01)	0.1140	356187	0.96(0.94-0.98)	2.90×10 ⁻⁵	0.182	1.1×10 ⁻⁴	1.6×10 ⁻³		
rs2227483	12q15	IL22(& IFNG) [‡]	A/T	0.44	102762 (21)	0.94(0.92-0.97)	2.27×10 ⁻⁶	253446 (14)	0.94(0.92-0.96)	3.55×10 ⁻¹¹	356208	0.94(0.93-0.96)	6.66×10 ⁻¹⁶	0.664	6.7×10 ⁻¹⁶	1.2×10 ⁻¹⁷		
rs7146581	14q32.32	TRAF3	T/C	0.24	102760 (21)	0.95(0.92-0.97)	1.44×10 ⁻⁴	256971 (15)	0.96(0.94-0.98)	5.67×10 ⁻⁵	359731	0.95(0.94-0.97)	6.17×10 ⁻⁸	0.219	1.2×10 ⁻⁴	4.1×10 ⁻⁶		
rs11657987	17q25.3	PGS1(SOCS3) [‡]	T/G	0.49	100695 (21)	1.06(1.04-1.09)	1.07×10 ⁻⁶	257019 (15)	1.03(1.01-1.05)	1.04×10 ⁻³	357714	1.04(1.03-1.06)	5.09×10 ⁻⁸	0.235	9.7×10 ⁻⁵	6.0×10 ⁻⁵		
rs77714197	19q13.11	CEBPA	T/C	0.02	87690 (14)	1.35(1.19-1.54)	3.31×10 ⁻⁶	256447 (14)	0.98(0.89-1.08)	0.6540	344137	1.10(1.02-1.18)	0.0139	0.048	0.102	0.116		

* rs11923593 replaces rs7625909 ($r^2=0.98$), rs2143950 replaces rs2038255 ($r^2=0.94$), rs17881320 replaces rs12951971 ($r^2=0.75$) in the replication analysis

[†] rs1799986 is within LRP1, but was selected in the MAGENTA analysis due to its proximity to STAT6. rs2227483 is with IL22, but was selected due to its proximity to both IL22 and IFNG. rs11657987 is within PGS1, but was selected due to its proximity to SOCS3

*Replication p-values for a 1-sided test

Replication p-values in **bold** were considered significant ($p < 0.0025$), overall p-values in **bold** are genome-wide significant, heterogeneity p-values < 0.05 are in bold

EA/OA = effect allele/other allele, EAF = effect allele frequency, OR = odds ratio, CI = confidence interval, N = sample size, het = heterogeneity